# Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects

> **NCT02060019** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 57 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.

## Key facts

- **NCT ID:** NCT02060019
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2014-06
- **Final completion:** 2014-12
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2016-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02060019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02060019, "Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02060019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*